Avalo Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for AVTX, updated each market day.
AVTX AI Sentiment
AI sees no strong directional signal for Avalo Therapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Avalo Therapeutics, Inc. Common Stock
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
Sector
Exchange
Market Cap
$323,823,902
Cap Tier
Employees
33
Headquarters
WAYNE, PA
Listed Since
Nov. 13, 2015
Website
AVTX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
AVTX Volatility
Avalo Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
